Glenmark Life Sciences Ltd

Glenmark Life Sciences Ltd | Sector: Pharmaceuticals | ISIN: INE03Q201024

₹ 391.70 (-5.18%) icon

24 Mar, 2023, 3:46:19 PM
Open
₹ 400.00
Prev. Close
₹ 413.10
Turnover(lac)
₹ 687.83
Day's High
₹ 400.00
Day's Low
₹ 389.10
52 Wk High
₹ 534.00
52 Wk Low
₹ 370.00
Book Value
₹ 193.83
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 4,799.39
P/E
11.45
EPS
34.24
Div. Yield
5.36

Stock View

info icon
Edit Image

STRONG BUY

Target | 30 Jan, 2023

551 (40.67%)

Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The C... Read More

KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 3/24/2023 3:46:19 PM

    ₹ 391.7 -21.40 -5.18
  • Open
  • ₹ 400
  • Prev. Close
  • ₹ 413.1
  • Turnover(Lac.)
  • ₹ 688
  • Day's High
  • ₹ 400
  • Day's Low
  • ₹ 389.1
  • 52 Week's High
  • ₹ 534
  • 52 Week's Low
  • ₹ 370
  • Book Value
  • ₹ 193.83
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 4,799.39
  • P/E
  • 11.45
  • EPS
  • 34.24
  • Divi. Yield
  • 5.36

Corporate Actions

16 Mar , 2023

12:00 AM

Dividend

Dividend amount: 21
Announcement date: 16 Mar , 2023

View Details

09 Mar , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 Jan , 2023

12:00 AM

14 Oct , 2022

12:00 AM

14 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

24 Aug , 2022

12:00 AM

AGM

Announcement date: 24 Aug , 2022

View Details

21 Apr , 2022

12:00 AM

Dividend

Dividend amount: 10.5
Announcement date: 21 Apr , 2022

View Details

22 Jul , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

22 Jul , 2022

12:00 AM

13 Apr , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 Apr , 2022

12:00 AM

24 Aug , 2022

12:00 AM

BookCloser

View Details

SHAREHOLDING SNAPSHOT
25 March , 2023 | 06:21 AM

PROMOTER - TOTAL82.85%

Indian: 82.85%

Foreign: 0%

NON-PROMOTER - TOTAL 17.15%

Institutions: 4.55%

Non-Institutions: 12.60%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Glenmark Life Sciences Ltd News and Update

Image not found
  • 23 hours ago |
  • 4:03 PM

According to a BSE filing, the parties to the proposed transaction, for which a legally binding memorandum of understanding had previously been signed, had "executed a Share Purchase Agreement and finalized the transaction."

Article Image
  • IIFL News Service |
  • 1 day ago |
  • 4:02 PM
ad IconAd Image

FINANCIALS

No Data Available To Display Chart

PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Glenmark Life Sciences Ltd

  • Glenn Saldanha

  • Chairman & Non Executive Dir.
  • Yasir Yusufali Rawjee

  • Managing Director & CEO

Summary

The company was incorporated as Zorg Laboratories Private Limited, a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune (RoC). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019.The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The companys R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh.During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs. 10/- each on the conversion of loan given to Director. During the year, 15,00,000... Read More


Reports by Glenmark Life Sciences Ltd


Reports by Glenmark Life Sciences Ltd